Вывод просто прекрасен.
In conclusion, this randomized trial demonstrated adding P-AscH- to gemcitabine and nab-paclitaxel yielded increased OS and PFS without the added hematologic toxicity [31,41]. Quality of life as assessed by the EORTC QLQ-C30 remained consistent between arms, without an apparent treatment associated degradation (Supplementary Table S4) [41]. Although limited by small sample size and a lack of diversity (Supplementary Table S8), this randomized, actively controlled trial provides key data regarding effect size to design a phase 3 trial to assess effectiveness of P-AscH-with metastatic PDAC as well as its generalizability to a larger population. Additionally, it provides data suggesting P-AscH– increasing the tolerability of cytotoxic chemotherapy.
Л. Полинг тоже, знаете, был лауреатом двух Нобелевских премий, но что-то до сих пор высокими дозами Витамина С мы не лечим все вокруг.
Нет слов просто...
@Ebm_base